Changes in sebum levels and the development of acneiform rash in patients with non–small cell lung cancer after treatment with EGFR inhibitors

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 259-263

  Nakahara, Takeshi ^a   Moroi, Yoichi ^a   Takayama, Koichi ^b   Itoh, Eriko ^a   Kido Nakahara, Makiko ^a   Nakanishi, Yoichi ^b   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cutaneous adverse event; Erlotinib; Geftinib; Skin toxicity

Indexed keywords

ERLOTINIB; GEFITINIB;

ACNE; ADULT; AGED; ARTICLE; BACK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FACE; FEMALE; HUMAN; MALE; NON SMALL CELL LUNG CANCER; SEBACEOUS GLAND; SEBUM; SEBUM PRODUCTION METER; SKIN MANIFESTATION; THORAX; TISSUE LEVEL;

EID: 84922176642     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S76860     Document Type: Article

References (11)

1. Cufer T, Ovcaricek T, O’Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013;49(6):1216–1225.
2. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812.
3. Orditura M, De Vita F, Galizia G, et al. Correlation between effcacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep. 2009;21(4):1023–1028.
4. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048.
5. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and effcacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913–3921.
6. Takata T, Tarutani M, Zouboulis CC, Sano S. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. J Dermatol Sci. 2012;66(2):165–168.
7. Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer. 2010;46(11):2010–2019.
8. Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents infammation. Sci Transl Med. 2013;5(199):199ra111.
9. Mascia F, Lam G, Keith C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med. 2013;5(199):199ra110.
10. Iwata C, Akimoto N, Sato T, Morokuma Y, Ito A. Augmentation of lipogenesis by 15-deoxy-Delta12,14-prostaglandin J2 in hamster sebaceous glands: identifcation of cytochrome P-450-mediated 15-deoxy-Delta12,14-prostaglandin J2 production. J Invest Dermatol. 2005; 125(5):865–872.
11. Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prosta-glandin E2 are active in sebaceous glands. J Mol Med (Berl). 2006; 84(1):75–87.